阿托伐他汀钙联合沙库巴曲缬沙坦钠对稳定性冠心病患者PCI术后血压和心功能的影响

doi:10.3969/j.issn.1671-7171.2026.01.025

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1172 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】 探讨阿托伐他汀钙联合沙库巴曲缬沙坦钠对稳定性冠心病患者经皮冠状动脉介入治疗(PCI)术后血压和心功能的影响。【方法】 回顾性分析2021年10月至2024年10月本院收治的82例稳定性冠心病患者的临床资料,根据患者治疗方案的不同将其分为观察组和对照组,每组41例。两组患者均行PCI,对照组患者术后服用阿托伐他汀钙,观察组患者在对照组的基础上联合服用沙库巴曲缬沙坦钠。比较两组患者治疗前后血压[收缩压(SBP)、舒张压(DBP)]、血脂指标[高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)]水平、心功能指标[左心室舒张末内径(LVEDD)、左心室收缩末内径(LVESD)、左室射血分数(LVEF)]、斑块指标[颈动脉内中膜厚度(IMT)、斑块厚度、斑块面积]。【结果】 治疗后,两组患者DBP、SBP均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组血清TC、TG、LDL-C水平均低于治疗前,HDL-C高于治疗前,且观察组血清TC、TG、LDL-C水平低于对照组,HDL-C高于对照组,差异有统计学意义(P<0.05);两组LVEDD、LVESD 低于治疗前,LVEF高于治疗前,且观察组LVEDD、LVESD 低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05);两组IMT、斑块厚度、斑块面积低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。【结论】 PCI术后服用阿托伐他汀钙及沙库巴曲缬沙坦钠能够有效改善患者的心功能和血压,降低血脂水平,抑制斑块累积,具有较好的应用效果。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王秀梅
	庄玉

关键词 ：冠心病, 阿托伐他汀, 缬沙坦, 血管成形术, 血压

Abstract：【Objective】 To explore the effects of atorvastatin calcium combined with sacubitril valsartan sodium on postoperative blood pressure and cardiac function in patients with stable coronary heart disease undergoing percutaneous coronary intervention(PCI). 【Methods】 A retrospective analysis was conducted on the clinical data of 82 stable coronary heart disease patients admitted to our hospital from October 2021 to October 2024. According to different treatment plans, the patients were divided into an observation group and a control group, with 41 cases in each group. Both groups of patients underwent PCI surgery. The control group received atorvastatin calcium after surgery, while the observation group received a combination of sacubitril and valsartan sodium in addition to the control group. The blood pressure [systolic blood pressure(SBP), diastolic blood pressure(DBP)], blood lipid levels[high-density lipoprotein cholesterol(HDL-C), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), triglycerides(TG)], cardiac function [left ventricular end diastolic diameter(LVEDD), left ventricular end systolic diameter(LVESD), left ventricular ejection fraction(LVEF)], and plaque indicators [carotid intima-media thickness(IMT), plaque thickness, plaque area] were compared between two groups of patients before and after treatment. 【Results】 After treatment, DBP and SBP in both groups of patients were lower than before treatment; And both DBP and SBP in the observation group were lower than those in the control group, with a statistically significant difference(P<0.05). The levels of serum TC, TG, and LDL-C in both groups were lower than before treatment, while HDL-C was higher than before treatment. The observation group had lower levels of serum TC, TG, and LDL-C than the control group, while HDL-C was higher than the control group, with statistical significance(P<0.05). The LVEDD and LVESD of the two groups were lower than before treatment, and the LVEF was higher than before treatment. The LVEDD and LVESD of the observation group were lower than those of the control group, and the LVEF was higher than that of the control group, with statistical significance(P<0.05). The IMT, plaque thickness, and plaque area of the two groups were lower than before treatment, and the values in the observation group were lower than those in the control group, with statistically significant differences(P<0.05). 【Conclusion】 Taking atorvastatin calcium and sacubitril valsartan sodium after PCI can effectively improve patients' cardiac function and blood pressure, reduce blood lipid levels, inhibit plaque accumulation, and have good application effects.

Key words： Coronary Disease Atorvastatin Valsartan Angioplasty Blood Pressure

收稿日期: 2025-06-06

中图分类号:

R541.4

引用本文:

王秀梅, 庄玉. 阿托伐他汀钙联合沙库巴曲缬沙坦钠对稳定性冠心病患者PCI术后血压和心功能的影响[J]. 医学临床研究, 2026, 43(1): 88-91.
WANG Xiumei^a, ZHUANG Yu^b. Effects of Atorvastatin Combined with Sacubitril/Valsartan Combination on Blood Pressure and Heart Function in Stable Coronary Heart Disease Patients Post-Percutaneous Coronary Intervention. JOURNAL OF CLINICAL RESEARCH, 2026, 43(1): 88-91.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2026.01.025 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2026/V43/I1/88

[1] 闻志楠,陈欣,刘迎午,等.不同程度冠状动脉病变冠心病患者的代谢组学特点及诊断价值[J].中国动脉硬化杂志,2020,28(2):134-140.
[2] 刘海伟,韩雅玲.冠心病介入抗栓治疗相关最新进展概要[J].中华心血管病杂志,2021,49(2):108-110.
[3] 许鹏,边兴花,王宇航.冠心病患者行经皮冠状动脉介入术后脂肪因子、炎性因子与肠道菌群对主要不良心血管事件的影响[J].实用临床医药杂志,2023,27(13):81-86.
[4] 康丽娟,李盼,耿丽颖,等.补体激活3a受体检测评估大剂量阿托伐他汀钙联合双联抗血小板治疗急性脑梗死的效果研究[J].河北医科大学学报,2023,44(9):1011-1016.
[5] 王本文,周睿,蒋煜,等.沙库巴曲缬沙坦钠联合卡维地洛治疗不同病因老年人慢性心力衰竭的有效性和安全性分析[J].中国现代医学杂志,2022,32(4):84-88.
[6] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会, 等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9): 680-694.
[7] ZHEN L. Effect of nursing intervention based on psycho-cardiology medicine model after PCI in elderly patients with coronary heart disease[J].Asian J Surg,2024,47(5):2304-2305.
[8] 孙孟雄,杨帅,支雄丽,等.冠心病患者阿托伐他汀钙治疗后血清补体及血脂指标的表达及意义[J].实用临床医药杂志,2022,26(24):71-75.
[9] 张祖涛,廖威,章楠,等.沙库巴曲缬沙坦钠与缬沙坦对老年冠心病PCI 术后患者心肌酶谱 NT-proBNP 及炎症因子的影响[J].河北医学,2023,29(2):344-349.
[10] FILPPULA A M, HIRVENSALO P, PARVIAINEN H, et al. Comparative hepatic and intestinal metabolism and pharmacodynamics of statins[J].Drug Metab Dispos,2021,49(8):658-667.
[11] ZHANG M S, ZOU Y F, LI Y X, et al. The history and mystery of sacubitril/valsartan: From clinical trial to the real world[J].Front Cardiovasc Med,2023, 10:1102521.
[12] CHEN J S, PEI Y, WANG Q Y, et al. Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension[J].J Hypertens,2023, 41(7):1077-1083.
[13] ZHENG P, WU H F, GU Y L, et al. Atorvastatin ameliorates lipid overload-induced mitochondrial dysfunction and myocardial hypertrophy by decreasing fatty acid oxidation through inactivation of the p-STAT3/CPT1 pathway[J].Biomed Pharmacother,2023, 157:114024.
[14] SHU J, GU Y W, JIN L, et al. Matrix metalloproteinase 3 regulates angiotensin Ⅱ induced myocardial fibrosis cell viability, migration and apoptosis[J].Mol Med Rep,2021, 23(2):151.
[15] FIGUEIREDO C S, ROSEIRA E S, VIANA T T, et al. Inflammation in coronary atherosclerosis: insights into pathogenesis and therapeutic potential of anti-inflammatory drugs[J].Pharmaceuticals(Basel),2023, 16(9):1242.
[16] DOCHERTY K F, VADUGANATHAN M, SOLOMON S D,et al. Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF[J].JACC Heart Fail,2020, 8(10):800-810.